Streetbeat News

Products Services

DAT

FIVN

Five9, Inc. (NASDAQ:FIVN) shares are trading lower due to a revenue guidance cut for 2024, despite beating Q2 revenue and EPS estimates. Analysts have lowered price targets but maintain positive ratings, citing potential profitability and AI benefits. ProShares Big Data Refiners ETF (NYSE:DAT) offers exposure to FIVN.

Portfolio Pulse from Lekha Gupta

August 09, 2024 | 5:39 pm

AAP

AMZN

BKNG

CAVA

HLT

NKE

RCL

TSLA

The article highlights significant options activity in the Consumer Discretionary sector, focusing on trades involving companies like TSLA, NKE, RCL, SG, GM, AMZN, AAP, CAVA, HLT, and BKNG. These activities include both bullish and bearish sentiments, with varying expiration dates and strike prices.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 5:35 pm

SNY

SPRY

The FDA has approved ARS Pharmaceuticals Inc's (NASDAQ: SPRY) Neffy nasal spray for emergency allergy treatment, providing an alternative to EpiPen and other autoinjectors like Sanofi SA's (NASDAQ: SNY) Auvi-Q. This approval comes ahead of the PDUFA target action date and is based on studies showing comparable efficacy to existing epinephrine injection products.

Portfolio Pulse from Vandana Singh

August 09, 2024 | 5:34 pm

DIS

SPY

VOO

Walt Disney Co (NYSE:DIS) is experiencing a significant resurgence in 2024, driven by record-breaking box office hits like 'Inside Out 2' and 'Deadpool & Wolverine.' The company has reached $3 billion in global ticket sales with just four releases. Disney's fiscal Q3 2024 revenue grew by 4% year-on-year, beating estimates. Investors can gain exposure to Disney through SPDR S&P 500 (NYSE:SPY) and Vanguard S&P 500 ETF (NYSE:VOO).

Portfolio Pulse from Anusuya Lahiri

August 09, 2024 | 5:31 pm

HAPS

YETI

YETI Holdings, Inc. (NYSE:YETI) has been upgraded to Buy by BofA Securities with a raised price target of $55. Despite reporting strong Q2 results and raising FY24 guidance, YETI shares are down 4.26%. The company is expected to benefit from global expansion, new products, and potential M&A activities.

Portfolio Pulse from Lekha Gupta

August 09, 2024 | 5:31 pm

HUGE

FSD Pharma shares are trading higher following the announcement by Celly Nutrition, a company backed by FSD Pharma, about the upcoming launch of its 'unbuzzd' recovery drink.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:25 pm

HUGE

FSD Pharma Inc. (NASDAQ:HUGE) shares are experiencing significant gains following an update on its investment in Celly Nutrition. The company announced the upcoming launch of its product, unbuzzd, on Amazon and the closing of its first round of financing. Trading volume for FSD Pharma shares has surged, with over 900 million shares traded compared to a float of 40.157 million shares.

Portfolio Pulse from Erica Kollmann

August 09, 2024 | 5:23 pm

VIRX

Viracta Therapeutics has received a Notice of Allowance for its U.S. Patent Application 18/240,853 titled 'HDAC INHIBITOR SOLID STATE FORMS (FOR THE TREATMENT OF CANCER, IMMUNE DISORDERS, AND INFLAMMATION)'.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:21 pm

STLA

Stellantis has announced the end of production of the Ram 1500 Classic at the Warren Truck Assembly Plant, leading to potential indefinite layoffs for about 2,450 employees starting as early as October 8. The plant will shift from a two-shift to a one-shift operating pattern in the General Assembly, while other operations will continue on two shifts to support Jeep Wagoneer production.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 5:18 pm

LYFT

LYFT Inc (NASDAQ:LYFT) shares are down 3.8% to $9.68 following the company's second-quarter earnings report. Despite strong results with adjusted EPS of $0.24 and revenue of $1.44 billion, the stock remains volatile. Lyft also reported significant improvements in free cash flow and active riders, and introduced a price lock feature. The company projects positive free cash flow for the full year.

Portfolio Pulse from Henry Khederian

August 09, 2024 | 5:10 pm